Status:
ACTIVE_NOT_RECRUITING
An Observational, Prospective, Multicenter Study to Evaluate the Biologic Use and Outcomes in Chinese Asthma Patients
Lead Sponsor:
AstraZeneca
Conditions:
Asthma
Eligibility:
All Genders
Brief Summary
This study is a multicenter, observational, prospective study to evaluate the asthma biologic use features and clinical outcomes in China. Patients will undergo clinical assessments and receive standa...
Detailed Description
This study is a multicenter, observational, prospective study to evaluate the asthma biologic use features and clinical outcomes in China. Patients will undergo clinical assessments and receive standa...
Eligibility Criteria
Inclusion
- Chinese, Female or Male
- Age: no limitation
- Physician-confirmed asthma diagnosis with documented evidence of diagnosis or evidence of variable expiratory airflow limitation (e.g., from bronchodilator reversibility testing or other tests).
- Participants or their legal guardians must be able to provide informed consent.
- Prescription of asthma biologics at enrolment.
Exclusion
- Participation in an interventional study within the last 3 months.
- Any significant disease or disorder which, in the opinion of the investigator, may either put the patient at risk because of participation in the study with the usage of biologics, or may influence the results of the study, or the patient's ability to participate in the study
Key Trial Info
Start Date :
November 14 2024
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 30 2026
Estimated Enrollment :
202 Patients enrolled
Trial Details
Trial ID
NCT06605885
Start Date
November 14 2024
End Date
September 30 2026
Last Update
September 25 2025
Active Locations (30)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Hohhot, China, China
2
Research Site
Beijing, China
3
Research Site
Changsha, China
4
Research Site
Chengdu, China